Glioblastoma (GBM)

Oncology
4
Pipeline Programs
5
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
1100%
+ 3 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

BD
1 program
1
silevertinib in combination with temozolomidePhase 21 trial
Active Trials
NCT07326566Not Yet RecruitingEst. Mar 2029
Trogenix
TrogenixUK - Edinburgh
1 program
1
TGX-007Phase 1/21 trial
Active Trials
NCT07346144Not Yet Recruiting68Est. Sep 2033
Laminar Pharmaceuticals
Laminar PharmaceuticalsSpain - Palma de Mallorca
1 program
1
LAM561Phase 11 trial
Active Trials
NCT03867123CompletedEst. Jul 2020
Leman Biotech
Leman BiotechChina - Shenzhen
1 program
1
Metabolically Armed EGFRvIII CAR-T cellsPhase 1Cell Therapy1 trial
Active Trials
NCT07244666Not Yet RecruitingEst. Dec 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Black Diamond Therapeuticssilevertinib in combination with temozolomide
TrogenixTGX-007
Leman BiotechMetabolically Armed EGFRvIII CAR-T cells
Laminar PharmaceuticalsLAM561

Clinical Trials (4)

Total enrollment: 68 patients across 4 trials

NCT07326566Black Diamond Therapeuticssilevertinib in combination with temozolomide

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Start: Apr 2026Est. completion: Mar 2029
Phase 2Not Yet Recruiting
NCT07346144TrogenixTGX-007

Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma

Start: Mar 2026Est. completion: Sep 203368 patients
Phase 1/2Not Yet Recruiting
NCT07244666Leman BiotechMetabolically Armed EGFRvIII CAR-T cells

Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma

Start: Nov 2025Est. completion: Dec 2028
Phase 1Not Yet Recruiting
NCT03867123Laminar PharmaceuticalsLAM561

A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients

Start: Dec 2018Est. completion: Jul 2020
Phase 1Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)